It is sold as a research reagent and is not FDA-approved for any human use
Considerations Individual variability: DSIPs effects seem highly person-specific
Liao CY, Xia WK, Feng YC, Li G, Liu H, Dou W, et al
Remember to vent the vial you are filtering into with a sterile needle
Lisco and colleagues published a review of the risks of GLP-1s and thyroid cancer in the journal Endocrine Connections in 2023, and although they describe evidence for a risk of thyroid cancer, they conclude: It is reasonable to continue prescribing GLP-1RAs due to the evidence of more relevant and well-recognized antihyperglycemic, cardiovascular, and renal benefits, with the management staying within current recommendations. If you are considering taking a GLP-1 but are concerned about the risk of thyroid cancer, you should discuss it with your doctor